Camino Pharma

Camino Pharma is a private, preclinical-stage biotech company pioneering novel allosteric modulators for oncology and neuropsychiatric disorders. Its core expertise lies in targeting historically difficult protein classes like PTPs and GPCRs, with programs in cancer signaling, addiction, and treatment-resistant depression. The company is led by a seasoned founder-CEO with a track record of venture fundraising and drug development, and it maintains strong academic ties with the Sanford Burnham Prebys Medical Discovery Institute. While still pre-revenue, it has secured non-dilutive grant funding from the National Institute on Drug Abuse (NIDA) for its addiction program.

Platform focused on discovering novel allosteric modulators of challenging protein classes, specifically protein tyrosine phosphatases (PTPs) and G-protein-coupled receptors (GPCRs), for oncology and CNS disorders.

In oncology, competitors include large pharma and biotechs pursuing novel kinase inhibitors and other targeted therapies, but few are focused on PTPs. In CNS, numerous companies are developing rapid-acting antidepressants (e.g., psychedelics, ketamine analogs), and several have pursued mGlu2/3 modulators historically, though with mixed success. Camino's niche is its specific focus on selective mGlu2 negative allosteric modulators.